These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 39479810)

  • 1. [Analysis of Clinical Characteristics and Prognosis of AML Patients with Co-Mutation of
    Yang XW; Li SS; Su YH; Sun JY; Gao YJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Oct; 32(5):1313-1316. PubMed ID: 39479810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Gene Profile and Clinical Significance of Concomitant Mutations in CN-AML Patients with
    Zhu J; Kang YF; Gao Y; Wang HW; Hao ZH; Wang HW
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):335-341. PubMed ID: 38660833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical Characteristics and Prognosis of Acute Myeloid Leukemia Patients with
    Shan RQ; Huang S; Gu ZY; Wang N; Liu DH; Dou LP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):327-334. PubMed ID: 38660832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GATA2 mutations in sporadic and familial acute myeloid leukaemia patients with CEBPA mutations.
    Green CL; Tawana K; Hills RK; Bödör C; Fitzgibbon J; Inglott S; Ancliff P; Burnett AK; Linch DC; Gale RE
    Br J Haematol; 2013 Jun; 161(5):701-705. PubMed ID: 23560626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GATA2 mutations in patients with acute myeloid leukemia-paired samples analyses show that the mutation is unstable during disease evolution.
    Hou HA; Lin YC; Kuo YY; Chou WC; Lin CC; Liu CY; Chen CY; Lin LI; Tseng MH; Huang CF; Chiang YC; Liu MC; Liu CW; Tang JL; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Chen YC; Tien HF
    Ann Hematol; 2015 Feb; 94(2):211-21. PubMed ID: 25241285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia.
    Greif PA; Dufour A; Konstandin NP; Ksienzyk B; Zellmeier E; Tizazu B; Sturm J; Benthaus T; Herold T; Yaghmaie M; Dörge P; Hopfner KP; Hauser A; Graf A; Krebs S; Blum H; Kakadia PM; Schneider S; Hoster E; Schneider F; Stanulla M; Braess J; Sauerland MC; Berdel WE; Büchner T; Woermann BJ; Hiddemann W; Spiekermann K; Bohlander SK
    Blood; 2012 Jul; 120(2):395-403. PubMed ID: 22649106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of different CEBPA mutations on therapeutic outcome in acute myeloid leukemia.
    Zhao Y; Huang Y; Jiang L; Zhang Y; Liu F; Yan P; Yu G; Liu J; Jiang X
    Ann Hematol; 2024 Sep; 103(9):3595-3604. PubMed ID: 39020042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allele-specific expression of GATA2 due to epigenetic dysregulation in CEBPA double-mutant AML.
    Mulet-Lazaro R; van Herk S; Erpelinck C; Bindels E; Sanders MA; Vermeulen C; Renkens I; Valk P; Melnick AM; de Ridder J; Rehli M; Gebhard C; Delwel R; Wouters BJ
    Blood; 2021 Jul; 138(2):160-177. PubMed ID: 33831168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology Group.
    Tarlock K; Lamble AJ; Wang YC; Gerbing RB; Ries RE; Loken MR; Brodersen LE; Pardo L; Leonti A; Smith JL; Hylkema TA; Woods WG; Cooper TM; Kolb EA; Gamis AS; Aplenc R; Alonzo TA; Meshinchi S
    Blood; 2021 Sep; 138(13):1137-1147. PubMed ID: 33951732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TET2 lesions enhance the aggressiveness of CEBPA-mutant acute myeloid leukemia by rebalancing GATA2 expression.
    Heyes E; Wilhelmson AS; Wenzel A; Manhart G; Eder T; Schuster MB; Rzepa E; Pundhir S; D'Altri T; Frank AK; Gentil C; Woessmann J; Schoof EM; Meggendorfer M; Schwaller J; Haferlach T; Grebien F; Porse BT
    Nat Commun; 2023 Oct; 14(1):6185. PubMed ID: 37794021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CEBPA double-mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76·8% of cases with TET2 and GATA2 alterations impacting prognosis.
    Grossmann V; Haferlach C; Nadarajah N; Fasan A; Weissmann S; Roller A; Eder C; Stopp E; Kern W; Haferlach T; Kohlmann A; Schnittger S
    Br J Haematol; 2013 Jun; 161(5):649-658. PubMed ID: 23521373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant.
    Ahn JS; Kim JY; Kim HJ; Kim YK; Lee SS; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Minden MD; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
    Ann Hematol; 2016 Jan; 95(2):301-10. PubMed ID: 26537612
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Ren H; Hong M; Feng J; Hao Z; Chen X; Liang F; Wei W; Liang X; Wang H; Chen X
    Biomol Biomed; 2024 Feb; 24(4):982-989. PubMed ID: 38416121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CEBPA gene mutations in Egyptian acute myeloid leukemia patients: impact on prognosis.
    Awad MM; Aladle DA; Abousamra NK; Elghannam DM; Fawzy IM
    Hematology; 2013 Mar; 18(2):61-8. PubMed ID: 22990006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical features and prognostic factors in adult acute myeloid leukemia patients with FLT3-ITD and CEBPA gene co-mutation].
    Pei RR; Zhang RH; Yu JF; Jiang ZX; Sun H; Wan DM; Xie XS; Liu YF; Li T; Sun L
    Zhonghua Xue Ye Xue Za Zhi; 2020 Apr; 41(4):297-301. PubMed ID: 32447933
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study group.
    Theis F; Corbacioglu A; Gaidzik VI; Paschka P; Weber D; Bullinger L; Heuser M; Ganser A; Thol F; Schlegelberger B; Göhring G; Köhne CH; Germing U; Brossart P; Horst HA; Haase D; Götze K; Ringhoffer M; Fiedler W; Nachbaur D; Kindler T; Held G; Lübbert M; Wattad M; Salih HR; Krauter J; Döhner H; Schlenk RF; Döhner K
    Leukemia; 2016 Nov; 30(11):2248-2250. PubMed ID: 27375010
    [No Abstract]   [Full Text] [Related]  

  • 17. [Type of CEBPA mutations in acute myeloid leukemia and their effect on prognosis].
    Mao YY; Cai H; Cao XX; Feng J; Zhang L; Zhou DB; Li J
    Zhonghua Xue Ye Xue Za Zhi; 2024 Jun; 45(6):556-560. PubMed ID: 39134486
    [No Abstract]   [Full Text] [Related]  

  • 18. [NPM1 and CEBPA mutations in pediatric cytogenetically normal acute myeloid leukemia].
    Ruan M; Zhang L; Han C; Liu X; Ai X; Zhang J; Liu T; Yang W; Chen X; Guo Y; Wang S; Li Q; Zou Y; Chen Y; Zhu X
    Zhonghua Er Ke Za Zhi; 2014 Apr; 52(4):303-7. PubMed ID: 24915920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome.
    Taube F; Georgi JA; Kramer M; Stasik S; Middeke JM; Röllig C; Krug U; Krämer A; Scholl S; Hochhaus A; Brümmendorf TH; Naumann R; Petzold A; Mulet-Lazaro R; Valk PJM; Steffen B; Einsele H; Schaich M; Burchert A; Neubauer A; Schäfer-Eckart K; Schliemann C; Krause SW; Hänel M; Noppeney R; Kaiser U; Baldus CD; Kaufmann M; Herold S; Stölzel F; Sockel K; von Bonin M; Müller-Tidow C; Platzbecker U; Berdel WE; Serve H; Ehninger G; Bornhäuser M; Schetelig J; Thiede C;
    Blood; 2022 Jan; 139(1):87-103. PubMed ID: 34320176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [CEBPA gene mutation analysis in acute myeloid leukemia].
    Han C; Lin D; Ai XF; Wang F; Sun HY; Wang M; Mi YC; Wang JX; Ru K
    Zhonghua Xue Ye Xue Za Zhi; 2013 Jul; 34(7):566-71. PubMed ID: 23906447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.